Page last updated: 2024-11-12

actein

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

actein: a cyclolanostane from the Chinese drug Shoma; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10032468
CHEMBL ID3391990
CHEBI ID70241
SCHEMBL ID12311788
MeSH IDM0252855

Synonyms (32)

Synonym
ACON0_000183
NCGC00180046-01
MEGXP0_000289
ACON1_001879
18642-44-9
actein
BRD-K55497146-001-01-0
unii-i14qo4lw9v
beta-d-xylopyranoside, (3beta,12beta)-12-(acetyloxy)-16,23:23,26:24,25-triepoxy-26-hydroxy-9,19-cycloanostan-3-yl
i14qo4lw9v ,
CHEBI:70241 ,
SCHEMBL12311788
26s-actein
actein [who-dd]
26s-actein (constituent of black cohosh) [dsc]
actein [usp-rs]
actein, (-)-
.beta.-d-xylopyranoside, (3.beta.,12.beta.,16.beta.,23r,24r,25s,26s)-12-(acetyloxy)-16,23:23,26:24,25-triepoxy-26-hydroxy-9,19-cyclolanostan-3-yl
DTXSID7033153 ,
CHEMBL3391990
actein, united states pharmacopeia (usp) reference standard
AKOS032962095
Q27138579
[(1s,1'r,2s,3'r,4r,4'r,5r,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-2-hydroxy-1,4',6',12',17',17'-hexamethyl-18'-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyspiro[3,6-dioxabicyclo[3.1.0]hexane-4,8'-9-oxahexacyclo[11.9.0.01,21.04,12.05,10.016,21]docosane]-3'-
HY-N6872
CS-0082050
MS-31074
[(1'r,3'r,4'r,5'r,6'r,12's,13's,16'r,18's,21'r)-2-hydroxy-1,4',6',12',17',17'-hexamethyl-18'-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyspiro[3,6-dioxabicyclo[3.1.0]hexane-4,8'-9-oxahexacyclo[11.9.0.01,21.04,12.05,10.016,21]docosane]-3'-yl] acetate
b-d-xylopyranoside,(3b,12b,16b,23r,24r,25s,26s)-12-(acetyloxy)-16,23:23,26:24,25-triepoxy-26-hydroxy-9,19-cyclolanostan-3-yl
26s-actein (constituent of black cohosh)
dtxcid90819961
actein (usp-rs)

Research Excerpts

Overview

Actein is a triterpene glycoside isolated from the rhizomes of Cimicifuga foetida (Chinese herb "shengma") Actein could inhibit the growth of breast cancer cells.

ExcerptReferenceRelevance
"Actein is a natural triterpenoid glycoside, isolated from the rhizomes of Cimicifuga foetida, which have been demonstrated to be potential in the treatment of breast cancer previously. "( Development of actein derivatives as potent anti-triple negative breast cancer agents.
Chen, CH; Chen, Y; Huang, S; Li, D; Qiu, MH; Shao, LD; Xiao, WW; Zhang, H, 2023
)
2.71
"Actein is a tetracyclic triterpenoid compound, extracted from the rhizome of Cimicifuga foetida, exhibiting anticancer activities as previously reported. "( Actein induces apoptosis in leukemia cells through suppressing RhoA/ROCK1 signaling pathway.
Hong, Z; Hu, J; Sun, XZ; Wang, X; Zhang, RR; Zhou, WD, 2017
)
3.34
"Actein (AT) is a triterpene glycoside isolated from the rhizomes of "( Iron oxide magnetic nanoparticles combined with actein suppress non-small-cell lung cancer growth in a p53-dependent manner.
Chen, L; Meng, ZL; Wang, JP; Wang, MS; Xiong, YQ; Xu, J, 2017
)
2.15
"Actein is a triterpene glycoside isolated from the rhizomes of Cimicifuga foetida (Chinese herb "shengma") which could inhibit the growth of breast cancer cells. "( New potential beneficial effects of actein, a triterpene glycoside isolated from Cimicifuga species, in breast cancer treatment.
Gao, S; Kwok, HF; Lau, CB; Lee, JK; Nian, Y; Qiu, MH; Wong, CK; Wu, XX; Xie, S; Yue, GG, 2016
)
2.15

Treatment

Oral actein treatments (10-15 mg/kg) for 28 days resulted in decreasing mouse 4T1 breast tumor sizes and metastasis to lungs and livers. Treating MG-induced mitochondrial dysfunction by preventing mitochondrial membrane potential dissipation and adenosine triphosphate (ATP) loss.

ExcerptReferenceRelevance
"Oral actein treatments (10-15 mg/kg) for 28 days resulted in decreasing mouse 4T1 breast tumor sizes and metastasis to lungs and livers."( New potential beneficial effects of actein, a triterpene glycoside isolated from Cimicifuga species, in breast cancer treatment.
Gao, S; Kwok, HF; Lau, CB; Lee, JK; Nian, Y; Qiu, MH; Wong, CK; Wu, XX; Xie, S; Yue, GG, 2016
)
1.16
"Treatment with actein prior to MG exposure reduced MG-induced mitochondrial dysfunction by preventing mitochondrial membrane potential dissipation and adenosine triphosphate (ATP) loss."( Actein protects against methylglyoxal-induced oxidative damage in osteoblastic MC3T3-E1 cells.
Choi, EM; Chon, S; Suh, KS, 2017
)
2.24
"Treatment with actein altered the distribution of actin filaments and induced apoptosis in these cells."( Growth inhibitory activity of extracts and compounds from Cimicifuga species on human breast cancer cells.
Cruz, E; Einbond, LS; He, K; Kronenberg, F; Roller, M; Wen-Cai, Y; Wu, HA, 2008
)
0.69
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
triterpenoidAny terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1188358Cytotoxicity against human H460 cells after 48 hrs by MTT assay2014Journal of natural products, Sep-26, Volume: 77, Issue:9
Cycloartane triterpenoids and their glycosides from the rhizomes of Cimicifuga foetida.
AID1188361Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2014Journal of natural products, Sep-26, Volume: 77, Issue:9
Cycloartane triterpenoids and their glycosides from the rhizomes of Cimicifuga foetida.
AID566621Allosteric modulation of alpha1beta2gamma2S GABAA receptor expressed in Xenopus laevis oocytes assessed as stimulation of GABA-induced chloride current at 300 uM by electrophysiology2010Journal of natural products, Dec-27, Volume: 73, Issue:12
Bioactivity-guided isolation of GABA(A) receptor modulating constituents from the rhizomes of Actaea racemosa.
AID566620Allosteric modulation of alpha1beta2gamma2S GABAA receptor expressed in Xenopus laevis oocytes assessed as stimulation of GABA-induced chloride current at 100 uM by electrophysiology2010Journal of natural products, Dec-27, Volume: 73, Issue:12
Bioactivity-guided isolation of GABA(A) receptor modulating constituents from the rhizomes of Actaea racemosa.
AID1188357Cytotoxicity against human SMMC-7721 cells after 48 hrs by MTT assay2014Journal of natural products, Sep-26, Volume: 77, Issue:9
Cycloartane triterpenoids and their glycosides from the rhizomes of Cimicifuga foetida.
AID1188359Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2014Journal of natural products, Sep-26, Volume: 77, Issue:9
Cycloartane triterpenoids and their glycosides from the rhizomes of Cimicifuga foetida.
AID566622Allosteric modulation of alpha1beta2gamma2S GABAA receptor expressed in Xenopus laevis oocytes assessed as stimulation of GABA-induced chloride current by electrophysiology2010Journal of natural products, Dec-27, Volume: 73, Issue:12
Bioactivity-guided isolation of GABA(A) receptor modulating constituents from the rhizomes of Actaea racemosa.
AID1188360Cytotoxicity against human HeLa cells after 48 hrs by MTT assay2014Journal of natural products, Sep-26, Volume: 77, Issue:9
Cycloartane triterpenoids and their glycosides from the rhizomes of Cimicifuga foetida.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.03)18.7374
1990's1 (3.03)18.2507
2000's6 (18.18)29.6817
2010's18 (54.55)24.3611
2020's7 (21.21)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.41 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index5.44 (4.65)
Search Engine Demand Index107.44 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (66.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]